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The relationship between repetitive mild traumatic brain injury (r-mTBI) and Alzheimer’s
disease (AD) is well-recognized. However, the precise nature of how r-mTBI leads to or
precipitates AD pathogenesis is currently not understood. Plasma biomarkers potentially
provide non-invasive tools for detecting neurological changes in the brain, and can
reveal overlaps between long-term consequences of r-mTBI and AD. In this study we
address this by generating time-dependent molecular profiles of response to r-mTBI
and AD pathogenesis in mouse models using unbiased proteomic analyses. To model
AD, we used the well-validated hTau and PSAPP(APP/PS1) mouse models that develop
age-related tau and amyloid pathological features, respectively, and our well-established
model of r-mTBI in C57BL/6 mice. Plasma were collected at different ages (3, 9, and
15 months-old for hTau and PSAPP mice), encompassing pre-, peri- and post-“onset” of
the cognitive and neuropathological phenotypes, or at different timepoints after r-mTBI
(24 h, 3, 6, 9, and 12 months post-injury). Liquid chromatography/mass spectrometry
(LC-MS) approaches coupled with Tandem Mass Tag labeling technology were applied
to develop molecular profiles of protein species that were significantly differentially
expressed as a consequence of mTBI or AD. Mixed model ANOVA after Benjamini–
Hochberg correction, and a stringent cut-off identified 31 proteins significantly changing
in r-mTBI groups over time and, when compared with changes over time in sham mice,
13 of these were unique to the injured mice. The canonical pathways predicted to
be modulated by these changes were LXR/RXR activation, production of nitric oxide
and reactive oxygen species and complement systems. We identified 18 proteins
significantly changing in PSAPP mice and 19 proteins in hTau mice compared to their
wild-type littermates with aging. Six proteins were found to be significantly regulated
in all three models, i.e., r-mTBI, hTau, and PSAPP mice compared to their controls.
The top canonical pathways coincidently changing in all three models were LXR/RXR
activation, and production of nitric oxide and reactive oxygen species. This work
suggests potential biomarkers for TBI and AD pathogenesis and for the overlap between
these two, and warrant targeted investigation in human populations. Data are available
via ProteomeXchange with identifier PXD010664.
Keywords: mild-TBI, Alzheimer’s disease, hTau, PS1/APP, plasma biomarker, proteomics
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INTRODUCTION
Traumatic brain injury (TBI) is one of the major causes of death
and disability, and is also one of the largest risk factors for
neurodegenerative diseases such as Alzheimer’s disease (AD). In
particular, a history of repetitive mTBI (r-mTBI) or concussive
injuries, caused by contact sports or accidental injury, has
been shown to precipitate clinicopathological profiles of patients
many years after injury, and exacerbate neuropathological
lesions observed in autopsy AD brains (Gedye et al., 1989;
Mortimer et al., 1991; Fleminger et al., 2003; McKee et al.,
2009, 2013; Omalu et al., 2011). While many clinical studies
have evaluated the epidemiological link between TBI and AD,
there is still a considerable lack of understanding concerning the
molecular underpinnings between mTBI and AD. Thus, there
is a paramount need to explore this inter-relationship since the
ability to identify the molecular and cellular indicators of mTBI
could aid risk assessment for AD, prognosis, and evaluation of
treatment before a subject’s condition is exacerbated.
The diagnosis of mTBI can be very challenging for clinicians,
typically because mTBI remains undetected by structural
neuroimaging techniques. Blood based biomarkers are potential
tools for detecting neurological changes in the brain in a
non-invasive and easily accessible manner. Blood biomarkers
are being successfully used in some cardiovascular, metabolic
and neurodegenerative conditions as prognostic or diagnostic
markers (Vasan, 2006; Yong, 2014; Lleó et al., 2015; Jeromin
and Bowser, 2017). A large number of prospective blood based
biomarker studies have been conducted in AD, yielding some
candidate molecules that correlate with functional outcome
(Thambisetty et al., 2010a,b, 2011; Kiddle et al., 2012; Velayudhan
et al., 2012; Burnham et al., 2014; Ashton et al., 2015; Baird
et al., 2015). However, none have been accepted as a definitive
blood biomarker of AD. From the few mTBI studies which
have investigated blood based biomarkers, a significant role was
identified for astrocyte, axonal and proteosomal proteins in the
blood at relatively acute time points post-injury (DeKosky et al.,
2013; Shen et al., 2014; Kulbe and Geddes, 2016; Zetterberg
and Blennow, 2016; Meier et al., 2017; Mondello et al., 2017;
Oliver et al., 2018; Shahim et al., 2018). Some studies have also
shown a significant role for AD-related tau protein species (total
tau, caspase cleaved tau fragments, phosphorylated tau) in the
blood following mTBI in athletes and military personnel (Di
Battista et al., 2013; Neselius et al., 2013b; Shahim et al., 2014,
2016; Olivera et al., 2015; Rubenstein et al., 2015; Gill et al.,
2018). However, most of these human studies lack adequate
controls, and chronic (or longitudinal) time points that are more
relevant to the current at risk patients with a history of mTBI
exposures, some have also been based on acute studies and also
retrospective design reports, which have inherent limitations,
such as selection bias, substantial heterogeneity in patient
populations, variance in type/nature of injury and post-injury
intervals. These studies have also not been well-validated and
reproducible by independent laboratories in different prospective
cohorts of a variety of TBI patients.
Advances in the field have been observed with the FDA
authorizing marketing of the first blood test for serum
glial fibrillary acid protein (GFAP) and ubiquitin c-terminal
hydrolase-L1 (UCHL1) to aid in the acute evaluation of
concussion in adults (Okonkwo et al., 2013; Papa et al., 2016;
Welch et al., 2017). However, the utility of these markers as
diagnostic tools for mTBI, and their specificity remains in
question as others have reported negative results (Diaz-Arrastia
et al., 2014; Tenovuo et al., 2016; Mondello et al., 2017). A specific
and sensitive chronic-related biomarker for asymptomatic
individuals at risk for developing neurodegenerative diseases
many years after exposure to a history of multiple mTBI’s
also still remains lacking. Identification of such putative blood
based biomarkers will be helpful for diagnosis and management
of mTBI patients beyond the initial exposure to injuries.
Additionally, given this poorly established relationship between
repetitive mTBI and AD blood based biomarkers, there is an
urgent need to identify candidate markers that would aid in early
warnings and preventative therapies for r-mTBI patients if at risk
for AD.
Animal models are an important early platform for
conducting such studies because they can be conducted in
a controlled manner without the influence of confounding
variables observed in human studies. They thus facilitate more
global “omic” style analyses which can be used to identify specific
potential biomarkers which can then be targeted for investigation
in human samples. Preclinical models also afford the design
of prospective analyses of relevant biomaterials required for
molecular studies at extended time points across the lifespan.
Although biomarker studies have been conducted in a variety
of preclinical models of TBI (Gyorgy et al., 2011; Ahmed et al.,
2012; Rostami et al., 2012; Chase, 2014; Sharma et al., 2017),
there remains a scarcity in longitudinal studies for monitoring
chronic changes in blood biomarkers after repetitive mTBI.
To address this problem, we utilized our well established
animal model of repetitive mTBI to explore putative biomarkers
in the blood after injury. This model has been very well
characterized up to 2-years post-injury, and shows pathological
and behavioral changes comparable to those observed in
human mTBI patients, typified by deficits in spatial learning,
white matter damage, corpus callosum thinning, and glial
activation (Mouzon et al., 2012, 2014, 2018b; Ojo et al., 2013,
2015). For AD models we used the hTau transgenic model
of age-related tauopathy (mice expressing all six isoforms
of human tau, on a null murine tau background) and the
PSAPP mouse model of amyloid pathologies [carrying the
PS1(M146L), and APP(K670N, M671L) mutations], in which
emerging neurological and histopathological features have
been well characterized (Holcomb et al., 1998; Duff et al.,
2000; Arendash et al., 2001; Gordon et al., 2002; Andorfer
et al., 2003, 2005; Sadowski et al., 2004; Trinchese et al., 2004;
Polydoro et al., 2009). We have chosen to explore timepoints
encompassing pre-, peri- and post-“onset” of the cognitive and
neuropathological phenotypes (i.e., ages 3, 9, and 15 months in
the hTau and PSAPP mice) and timepoints post-injury of 24 h,
3, 6, 9, and 12 months in the r-mTBI mice in order to capture
anticipated responses overlapping with AD pathogenic changes.
We used a liquid chromatography and mass spectrometry
(LC/MS) proteomic based approach to interrogate plasma
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samples from these mouse models. An unbiased proteomics
approach represents a powerful tool to bring to bear in
molecular characterizations of neurodegenerative pathways
for therapeutic target discovery and biomarker identification.
We have successfully employed this approach to identify
biomarkers/molecular targets in mouse models of other
neurodegenerative diseases (Crawford et al., 2012; Zakirova
et al., 2017). In this study we provide a comprehensive timeline
of unique and converging molecular changes in the plasma, after
repetitive mTBI, and in the AD mouse models. This work lays
the groundwork for future validation and translational studies
in humans, to confirm the role of these identified proteins and
implicated molecular pathways as non-invasive systemic/plasma
biomarkers of repetitive mTBI sequelae and possible risk for AD
pathogenesis.
MATERIALS AND METHODS
Animals
Wild-type C57BL/6 mice and hTau transgenic mice expressing
human tau on a C57BL/6 and null murine tau background
(generated as previously described by Andorfer et al., 2003)
were purchased from Jackson Laboratories, Bar Harbor, ME.
PSAPP mice expressing PS1 and APP AD-causing mutations
[PS1(M146L), APP(K670N,M671L)] were bred in our vivarium
facility on a C57BL/6 background, wild-type littermate controls
were used as controls for PSAPP mice (see Figure 1).
hTau and PSAPP mice and their C57BL/6 littermate controls
were allowed to age until euthanasia at 3, 9, and 15 months of
age. C57BL/6 mice used for the r-mTBI study were 12 weeks old
at the time of injury. Animals were housed in standard cages
under a 12-h light/12-h dark schedule at ambient temperature
controlled between 22 and 23◦C under specific pathogen free
conditions. Animals were given food and water ad libitum
and maintained under veterinary supervision throughout the
study. There was no evidence of disease among the colony.
Male mice were randomly assigned to experimental groups with
a sample size of 4 per group. All mice were male to avoid
any confounding effects of gender and to limit the numbers
of mice required. Experiments were performed in accordance
with the Office of Laboratory Animal Welfare and National
Institutes of Health guidelines under a protocol approved by the
Roskamp Institute Institutional Animal Care and Use Committee
(IACUC – R054). All analyses were carried out blind to study
group assignment.
Experimental mTBI
The experimental TBI methods were performed as previously
described (Mouzon et al., 2012). Briefly, mice were anesthetized
with 1.5 L per minute of oxygen and 3% isoflurane for 3 min.
After shaving of the injury site, mice were transferred into a
stereotaxic frame (Just For Mice Stereotaxic, Stoelting, Wood
Dale, IL, United States) mounted with an electromagnetic
controlled impact device (Impact One Stereotaxic Motorized
Impactor, Richmond, IL, United States). Heads were positioned
and fixed in the device, which prevented lateral movements as
FIGURE 1 | Experimental design and timeline of repetitive mTBI and AD
mouse models. Six different groups of mice were used in this study. The mTBI
group consisted of C57BL/6 mice exposed to sham and repetitive mTBI injury
at 8–12 weeks of age, and euthanized at 24 h, 3, 6, 9, and 12 months
post-injury for proteomic analyses (A). The tauopathy group consisted of hTau
and background strain C57BL/6 mice euthanized at 3, 9, and 15 months of
age (B). The amyloidogenesis group consisted of PSAPP (PS1/APP) and
inbred background strain C57BL/6 mice euthanized at 3, 9, and 15 months of
age (C). N = 4 per group at each timepoint and age.
the impact was delivered. All mice were placed on a heating pad
to maintain their body temperature at 37◦C. A 5-mm blunt metal
impactor tip attached to the electromagnetic motorized device
was zeroed on the scalp and positioned above the midsagittal
suture before each impact using the NeuroLab controller. On
satisfactory positioning, the tip was retracted and the depth was
adjusted to the desired level. The scalp was gently stretched by
hand to restrict lateralization of the impact and to prevent the
rod from delivering an inadequate trauma load at an irregular
angle. Injury parameters were 5 m per second strike velocity,
1.0 mm strike depth, 200 ms dwell time, and a force of 72N.
This sublethal impact does not cause direct tissue damage to
the injury site, and there is no development of skull fracture or
subdural hemorrhage, even after repetitive injuries. Mice in the
r-TBI group received 5 hits over a 9-day period with an inter-
injury interval of 48 h. Repetitive sham control mice received
anesthesias of the same frequency and duration (∼3 min per
session) as their r-TBI counterparts. After each impact was
delivered, the mice were allowed to recover on a heating pad
set at 37◦C to prevent hypothermia. On becoming ambulatory,
mice were returned to their cages and carefully monitored for any
abnormalities.
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Plasma Protein Fractionation
A novel fractionation approach was utilized that enables
albumin and hemoglobin depletion from precipitated plasma
or serum samples. While approach does not achieve the same
level of abundant protein depletion as can be obtained via
immunoaffinity approaches, it was chosen over established
solvent-based or chromatographic depletion of abundant plasma
proteins. A key attribute of this fractionation protocol is that
it enables downstream lipidomic and/or metabolomic sample
preparation from the same sample aliquot, as there is no
addition of non-volatile salts to the crude sample at any step –
a critical feature when dealing with sample-limited situations
such wherein poly-omic comparisons of mouse plasma are
planned.
Briefly, 50 µl plasma samples were precipitated by addition
of 7 volumes of methanol and centrifuged at 21,000 × g RCF
at room temperature for 1 min, and the supernatant fraction
saved. 200 µl of hexane was added to the pellet, and the
pellet disrupted by bath sonication for 1 min, followed by
centrifugation to pellet the insoluble material. This process
was repeated, though with the addition of 2:1 isopropanol :
hexane in lieu of 100% hexane. [note: These solvent supernatants
were pooled, saved, and stored at −80◦C for future lipidomic
and metabolomic analysis by GC- and LC-MS/MS approaches].
The resultant pellet was then sonicated in the presence of
100 µl of 58% v/v hexafluroisopropanol (HFIPA) in water, and
centrifuged at 20,000 × g RCF for 1 min. The supernatant
(containing an albumin- and Hb-depleted plasma protein
fraction was transferred to a new tube, and the fraction
precipitated with the addition of four volumes of chilled acetone
to remove the HFIPA. This pellet was re-suspended in 10X
reduction/alkylation/denaturation buffer [20 mM TEAB, 1 mM
TCEP, 2.5 mM C-AM, and 5% w/v sodium deoxycholate (SDC)]
by bath sonication, and incubated at 37◦C in darkness for 30 min
to allow for simultaneous reduction and alkylation. The samples
were then diluted 10-fold with addition of 20 mM TEAB, and
a 20 µl process aliquot taken for protein quantification using
the BCA assay, and SDS-PAGE to (1) verify the concentrations
obtained by BCA assay, and (2) to ensure the consistency and
integrity of the protein fractions prior to tryptic digestion and
TMT labeling.
Tryptic Digestion
Sequencing grade porcine trypsin (Promega, Wisconsin) was
added to 50 µg aliquots (at 1 µg/µl final protein concentration)
of depleted plasma at a 1:100 enzyme-to-substrate ratio and
incubated at 37◦C for 16 h. 10 µl of each was transferred to a
new tube following digestion and taken to dryness in a vacuum
centrifuge for anhydrous TMT labeling (below).
Tandem Mass Tag (TMT) Labeling
Briefly, we employed a multiplexed isobaric labeling strategy
to allow for simultaneous identification and quantification of
proteins from multiple biological samples. Six- and 10-plex
TMT labeling kits (Thermo Scientific, NJ, United States) were
used for analyses of protein samples from AD and TBI mouse
models, respectively. This format allowed all time points from
all genotypes and treatment groups to be analyzed within the
same batch. All three time points (3, 9, and 15 months) in the
AD mouse models (disease vs. control) were included in the
six-plex TMT kit. While all five time points (24 h, 3, 6, 9, and
12 months post-injury) in the TBI mouse model (r-sham vs.
r-TBI) were included in the 10 plex TMT kit. All samples and
isobaric label tags were handled blind to the experimenter. Each
TMT label was dissolved in 20 µl of acetonitrile solution. Ten
microliters of digested protein from each sample were taken to
dryness in a vacuum centrifuge. 20 µl aliquots of each label
were also dried down in the speed vacuum and subsequently
re-suspended in 25 mM TEAB in acetonitrile solution. Re-
suspended labels were added to dried protein samples, and
allowed to incubate for 1 h at room temperature, and the
reactions quenched with addition of formic acid to a final
concentration of 1% v/v. Labeled samples were pooled according
to their respective experimental batches and subsequently taken
to dryness in a vacuum centrifuge to remove acetonitrile prior to
sample cleanup.
Sample Clean Up
Residual SDC and TEAB were removed from the samples as
follows. The pooled, dried TMT-labeled protein samples were re-
suspended in 100 µl of 1% formic acid in water, and centrifuged
at 20,000 × g RCF for 1 min to remove the precipitated
SDC. The supernatants were collected in new tubes, into which
400 µl of ethyl acetate was added, followed by vortexing to
partition the residual SDC into the organic (upper) layer. Samples
were then centrifuged at 20,000 × g RCF for 30 s, and upper
organic layers were discarded. This was repeated three times,
and the final lower phase was taken to dryness in the speed
vacuum. Dried samples were re-suspended in 100 µl of 0.1%
formic acid. Pooled TMT-labeled samples were concentrated
and de-salted using C18 reversed phase ZipTips according to
manufacturer’s protocol. ZipTip eluates were re-suspended in
20 µl of 0.1% formic acid and transferred into an auto-sampler
vial, and analyzed by nano-UPLC MS on a Q-Exactive Orbitrap
instrument (Thermo).
Chromatography and Mass
Spectrometry Methods (LC-MS/MS)
Samples were analyzed by LC-MS/MS (Q-Exactive) as previously
described (Abdullah et al., 2011; Zakirova et al., 2017). Data
dependent acquisition (DDA) settings for the experiments were
as follows: full-scan MS resolution = 140,000 full width at
half maximum at 200 m/z, full-scan range = 380–1250 m/z,
isolation width = 1.2 m/z, higher energy C-trap dissociation
relative collision energy = 29, a minimum m/z setting of 100
m/z was used for all MS2 spectra, MS2 resolution = 17 500,
dynamic exclusion = 180 s, and a Top 15 high/low duty cycle was
used for precursor ion selection. These settings, particularly the
narrow isolation window and the ultra-long gradient, were used
to minimize the deleterious effects on quantitative accuracy that
result from co-isolation of isobaric precursors without resorting
to MS3-based methods.
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Data Processing and Statistical Analysis
of Proteomics Data
PMi Preview software was used to survey the data files
and, if necessary, to add other modifications to the search
criteria. Also, Preview results were used to choose the
precursor and fragment ion mass tolerances (4 ppm, 0.02 Da,
respectively) as well as dynamic modifications. The following
settings were used to search the data using SEQUEST and
BYONIC as the search algorithms, and Uniprot mouse database
(02/2016). Dynamic modifications − Oxidation/+15.995 Da
(M), Methyl/+14.016 Da (E), Deamidated/+0.984 Da (N, Q),
static modifications of TMT6plex/+229.163 Da (N-Terminus,
K), and Carbamidomethyl +57.021 (C). Only unique peptides
were considered for quantification purposes. For SEQUEST,
the Percolator feature of Proteome Discoverer, and for Byonic,
the target-decoy feature, were used to set a false discovery
rate (FDR) of 0.01 and peptides passing this cutoff value
were exported to JMP (SAS) 8.0.2 for data cleaning and
statistical analysis. Proteins identified in at least half of
the total number of plexes were used for the quantitative
analysis. After ln transformation of the raw ion counts, each
channel was normalized by central tendency normalization
where medians were used. The ratios were formed by dividing
injured or sham mice at 3, 6, 9, and 12 timepoints with
24 h time point within the respective group; likewise, 9 and
15 month old C57BL/6, hTau and PSAPP mice were divided
by their 3 months old counterparts on the plex. After the
median per peptide sequence from multiple fractions were
calculated, mixed model ANOVA was used to test for significant
proteins changing overtime within each group. The mass
spectrometry proteomics plasma data have been deposited to the
ProteomeXchange Consortium via the PRIDE (Vizcaíno et al.,
2016) partner repository with the dataset identifier PXD010664.
Note: For access to MS data, please use reviewer account
details - Username: reviewer60134@ebi.ac.uk and Password:
ma0JJzM9.
IPA Analysis
Datasets of significantly modulated proteins were uploaded
to the Ingenuity R© Pathway Analysis software (IPA, Ingenuity
Systems1) in order to map the proteins onto known networks
of protein interactions to ascertain the functional significance
of TBI and/or AD dependent changes in protein expression
in each experimental paradigm (Krämer et al., 2014). In IPA
the uploaded protein lists are assigned to established molecular
pathways (“Canonical pathways”) and biological functions in
the knowledgebase. The Core analysis settings were; Ingenuity
Knowledge base as reference set, maximum number of molecules
per network was 35, maximum number of networks for analysis
was 25. Only experimentally observed knowledge was used. All
species, data sources, tissues/cell lines included at the time of
the analysis in IPA was considered. Core analysis identified
the canonical pathways that were shown to be significantly
modulated in response to TBI or AD pathogenesis as a result
1www.ingenuity.com
of significant modulation of proteins represented in those
pathways. The significance of the association between the data
set and the canonical pathway was measured in two ways:
(1) For each canonical pathway a ratio of the number of
molecules from the data set that map to that pathway divided
by the total number of molecules in that canonical pathway is
displayed. (2) Fisher’s exact test was used to calculate a p-value
determining the probability that the association between the
proteins in the dataset and the canonical pathway is explained
by chance alone. P-values lower than 0.05 were considered
significant.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Enzyme-linked immunosorbent assay were conducted to validate
proteomic results, procedures were conducted according to
manufacturer guidelines.
RESULTS
Temporal Changes in Unique and
Common Proteins in the Plasma of
Repetitive mTBI and Sham Mice Across
Multiple Post-injury Time Points
A 10 plex TMT approach was used to study the proteomic
profiles in repetitive injured and sham mice at 5 multiple
time points post-injury (24 h, 3, 6, 9, and 12 months; see
Figure 2). A total of 191 non-redundant master protein groups
were observed. We interrogated 65 proteins that were identified
within all biological samples in the plexes. To explore the time
dependent profile of changes within each group, and to compare
temporal changes in unique and common protein profiles over
multiple time points between injured and sham mice, we have
analyzed our data sets using a mixed model ANOVA approach.
Samples were normalized to their 24 h post-injury/sham group,
and statistical analyses using mixed model ANOVA identified 8
proteins significantly changing over time only in sham mice, 13
proteins significantly changing only in injured mice over time,
and 28 common proteins significantly changing in both groups
overtime (Figure 2). A list of all significantly modulated proteins
in sham and injured mice across multiple time points post-injury
is in Table 1.
To Validate Our Proteomics Data
We used an antibody-based ELISA approach to measure
the levels of three selected proteins (complement factor I;
Leucine-rich HEV glycoprotein, and alpha-2-macroglobulin).
These proteins were selected on the basis that they were highly
abundant in our samples, were significantly modulated in
sham and/or injury, and easily detected by an established
antibody based ELISA approach. All three proteins showed
trends consistent with the TMT data; Complement I
Supplementary Figure S1 (TBI increased versus sham);
Leucine-rich HEV glycoprotein Supplementary Figure S2, and
alpha-2-macroglobulin Supplementary Figure S3.
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FIGURE 2 | Summary of tandem mass tag (TMT) labeling, liquid chromatography/mass spectrometry (LC/MS) and proteomic analyses of plasma samples from
repetitive mTBI and sham injured mice. Work flow showing randomization of samples for TMT labeling, pooling of samples for multiplexing with 10-plex TMT isotopic
mass tag labels, identified total number of quantra spectra, peptide spectrum match, protein groups analyzed in all plexes, and venn diagram showing significantly
regulated proteins changing across five multiple post-injury timepoints in plasma samples from sham and injured mice. Eight unique proteins were changing in sham
mice with age, 13 unique proteins were changing in r-mTBI mice over-time following injury, and 28 proteins were changing in both sham and injured mice with
age/time-point post-injury.
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Disease, Biofunctions and Canonical
Pathways Modulated in Plasma Samples
From Repetitive mTBI and Sham Mice
Across Multiple Post-injury Time Points
A list of 33 diseases and biofunctions modulated in sham
injury vs. repetitive mTBI groups across multiple time points
is shown in Figure 3. Some of these diseases and biofunctions
include growth of blood vessels, immune response of cells,
synthesis of eicosanoid, migration of phagocytes, synthesis and
metabolism of reactive oxygen species, secretion of lipids, transport
of steroids, and relaxation of arteries. Ingenuity Pathway Analyses
(IPA) identified the top three canonical pathways modulated
in the plasma of injury vs. sham groups following analyses
FIGURE 3 | Disease and Biofunctions modulated in sham injury and repetitive
mTBI plasma samples across multiple timepoints post-injury. Underlying
disease pathology and biofunctions generated from the list of significantly
modulated proteins in sham and injury groups across multiple timepoints
using Ingenuity pathway analyses (IPA).
FIGURE 4 | Canonical pathways modulated in sham injury and repetitive
mTBI plasma samples across multiple timepoints post-injury. Identified
canonical pathways generated from the list of significantly modulated proteins
in sham and injury groups across multiple timepoints using IPA. Top three
pathways include LXR/RXR activation, Production of Nitric oxide and Reactive
oxygen species, Complement system.
of significantly regulated proteins. These pathways include
LXR/RXR activation, Production of Nitric oxide and reactive
oxygen species, and complement systems (see Figure 4).
Temporal Changes in Unique and
Common Proteins in the Plasma of AD
Mouse Models of Tauopathy (hTau) and
Amyloidogenesis (PSAPP) at Different
Ages; and Commonalities With
Repetitive mTBI Model
A 6-plex TMT approach was used to study the proteomic profiles
across hTau vs. wild-type and PSAPP vs. wild-type mice at 3
different ages (3, 9, and 15 months; see Figure 5).
A total of 153 and 155 non-redundant master proteins were
identified from the PSAPP and hTau plexes, respectively; 49
proteins present in all biological samples in the hTau/WT plexes
were identified and analyzed in the hTau/WT study, and 65
proteins in the PSAPP/WT study (Figure 5). We explored
age-related changes in each disease genotype and compared
with their wild-type controls. This was designed to compare
genotype specific temporal profiles of unique and common
proteins significantly altered with aging. Age-related changes
were normalized to the 3-month age group for each genotype,
and datasets were analyzed using mixed model ANOVA. Within
the hTau group, 18 proteins were significantly altered in hTau
mice compared to wild type controls in the combined age groups,
26 proteins were changing with aging and common to both
hTau and WT controls, and 10 proteins showing an interaction
between genotype and age (Figure 5). Within the PSAPP group,
19 proteins were significantly altered in PSAPP mice compared
to their WT littermate controls in the combined age groups, four
proteins were altered with aging and common to both hTau and
WT controls, and four proteins showing an interaction between
genotype and age (Figure 5). A list of all significantly modulated
plasma proteins in the PSAPP vs. wild type groups is shown
in Table 2; and likewise Table 3 shows significantly modulated
plasma proteins in the hTau vs. wild type groups.
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FIGURE 5 | Summary of TMT labeling, LC/MS and proteomic analyses of hTau and PSAPP mouse models. Work flow showing randomization of samples for TMT
labeling, pooling of samples for multiplexing with 6-plex TMT isotopic mass tag labels, identified total number of master proteins, protein groups analyzed in all
plexes, and significantly regulated proteins changing across three multiple timepoint of ages in plasma samples from hTau and PSAPP mice compared to their wild
type controls. In the PSAPP group, 18 proteins were changing compared to wild type mice in the combined age groups, 26 changing with age in both groups, and
10 showing an interaction between genotype and aging. In the hTau group, 19 proteins were changing compared to wild type mice in the combined age groups, 4
changing with aging in both groups, and 4 showing an interaction between genotype and aging.
TABLE 2 | Significantly modulated proteins changing with age in plasma samples from PSAPP vs. wild type littermate mice.
M.P.A Description P-value Wild type mice PSAPP(APP/PS1) Mice
9 months 15 months 9 months 15 months
Q00896 Alpha-l-antitrypsin 1–3 P < 0.01 → 0.047 ↓ −0.189 → −0.005 → 0.078
Q00898 Alpha-1-antitrypsin 1–5 P < 0.01 ↓ −0.472 ↓ −0.381 → 0.020 ↓ −0.274
Q61838 Alpha-2-macroglobulin P < 0.001 ↓ −0.026 ↓ −0.033 ↓ −0.125 ↓ −0.213
Q00623 Apolipoprotein A-l P < 0.0001 → 0.071 → 0.142 → 0.158 → 0.258
P06728 Apolipoprotein A-IV P < 0.05 ↓ −0.067 → 0.076 → −0.004 → 0.089
Q9Z1R3 Apolipoprotein M P < 0.01 ↓ −0.069 ↓- −0.067 → 0.331 → 0.252
Q91X72 Hemopexin P < 0.0001 ↓ −0.293 ↓ −0.349 ↓ −0.426 ↓ −0.441
P01837 Ig kappa chain C region P < 0.05 → 0.424 ↑ 0.608 → 0.365 → 0.363
P01872 Ig mu chain C region P < 0.01 → 0.383 ↑ 0.919 → 0.395 → 0.400
P20918 Plasminogen P < 0.05 ↓ −0.130 → 0.075 ↓ −0.300 ↓ −0.105
A0A075B5M7 Protein lgkv5-39 P < 0.01 → 0.061 → 0.363 → 0.149 → 0.041
Q921I1 Serotransferrin P < 0.0001 → 0.070 → 0.219 → 0.068 → 0.126
P07724 Serum albumin P < 0.0001 → 0.274 → 0.299 → 0.101 → 0.064
Purple text represent lists of unique proteins significantly modulated in PSAPP group alone. Red text represent list of proteins significantly modulated in injury (repetitive-
mTBI) and AD mouse models of tauopathy (hTau) and amyloidogenesis (PSAPP). Values represent least squared mean generated following logarithmic transformation of
calculated differences in protein expression levels after normalization with 3 months old mice from each genotype group. P-value represents FDR adjusted p-value after
Benjamin–Hochberg correction and Mixed model ANOVA. MPA, master protein accessions.
We compared the significant proteomic profiles observed in
all three different models to establish any unique or convergent
molecular profiles between both AD models and following
repetitive mTBI (see Table 4). Of the significantly regulated
proteins observed to be changing with age or time post-injury
in the PSAPP vs. WT littermate study (23), hTau vs. WT study
(35), and the r-mTBI study (41), multiple comparisons of these
proteins identified that three were unique to each of the PSAPP
and hTau study, and 27 were unique to the r-mTBI study.
Moreover, multiple comparisons also identified that six of these
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TABLE 3 | Significantly modulated proteins changing with age in plasma samples from hTau vs. C57BL/6 mice.
M.P.A Description P-value C57BL/6 MICE hTau MICE
9 months 15 months 9 months 15 months
Q00623 Apolipoprotein A-I 1.3E-12 → −0.14 → −0.14 → 0.28 → −0.10
P07758 Alpha-1-antitrypsin 1–1 0.0320 ↓ −0.27 → 0.53 → −0.15 → 0.36
Q00898 Alpha-1-antitrypsin 1–5 2.1E-06 ↓ -1.63 ↓ -1.49 ↓ -1.27 ↓ −0.47
P29699 Alpha-2-HS-glycoprotein 0.0172 ↓ −0.54 → −0.05 ↓ −0.26 → 0.20
A8DUK4 Beta-globin 0.0187 → 0.28 ↓ −0.30 → 0.23 → 0.41
Q06890 Clusterin 0.0094 ↓ −0.17 → 0.34 ↓ −0.35 → 0.03
Q80YC5 Coagulation factor XII 0.0016 ↓ −0.51 → 0.01 → 0.14 → 0.29
Q06770 Corticosteroid-binding globulin 2.8E-05 → 0.50 → 1.06 → 0.10 → 0.50
P01898 H-2 class 1 antigen, Q10 alpha chain 0.0036 → −0.07 → 0.20 → 0.14 → −0.11
P01942 Hemoglobin subunit alpha 0.0193 → 0.43 ↓ −0.26 → 0.43 → 0.50
Q91X72 Hemopexin 6.0E-06 ↓ −0.65 → −0.16 ↓ −0.37 → −0.07
P01837 Ig kappa chain C region 0.0006 → 1.05 → 0.97 ↑ 1.39 ↑ 1.53
P01872 Ig mu chain C region 0.0417 → 1.11 → 0.67 → 0.89 → 1.09
008677 Kininogen-1 1.8E-09 → −0.08 → 0.52 ↓ −0.28 → 0.20
P28665 Murinoglobulin-1 0.0226 ↓ −0.33 → −0.02 → 0.02 → −0.05
F6TQW2 Protein Ighg2c 3.5E-05 → 1.24 ↑ 1.63 ↑ 2.81 ↑ 2.29
Q00724 Retinol-binding protein 4 0.0021 ↓ −0.18 → −0.08 → 0.20 → 0.04
P07759 Serine protease inhibitor A3K 0.0136 ↓ −0.52 → −0.06 ↓ −0.18 → −0.06
P07724 Serum albumin 2.6E-12 → −0.11 ↓ −0.49 → 0.40 ↓ −0.20
P61939 Thyroxine-binding globulin 0.0103 → 0.82 → 1.24 → 0.41 → 0.52
P07309 Transthyretin 4.0E-05 → 0.05 → 0.56 → −0.15 → 0.13
Purple text represent lists of unique proteins significantly modulated in hTau group alone. Red text represent list of proteins significantly modulated in injury (repetitive-
mTBI) and AD mouse models of tauopathy (hTau) and amyloidogenesis (PSAPP). Values represent least squared mean generated following logarithmic transformation of
calculated differences in protein expression levels after normalization with 3 months old mice from each genotype group. P-value represents FDR adjusted p-value after
Benjamin–Hochberg correction and Mixed model ANOVA. MPA, master protein accessions.
significantly modulated proteins were common to PSAPP/WT
and hTau/WT group, 10 were common in the PSAPP/WT group
and r-mTBI study, and eighteen were common to the hTau/WT
group and r-mTBI study. Only six proteins were found to be
significantly altered in all three mouse models with aging or time
post-injury.
Ingenuity pathway analyses (IPA) generated three canonical
pathways in each of the PSAPP and hTau studies that were
significantly regulated with age compared to their WT controls,
after Benjamini–Hochberg correction and fisher exact test cut-
off at P < 0.01. In the PSAPP group these pathways were acute
phase response signaling, LXR/RXR activation, and Production
of Nitric oxide and reactive oxygen species (Figure 6). In the
hTau group, the latter two canonical pathways were also in
the 3 significantly modulated, along with the coagulation system
(Figure 7). Thus, significant modulation of both LXR/RXR
activation and Production of nitric oxide/reactive oxygen species
was common to ALL three different mouse models.
DISCUSSION
This study was designed to address the lack of prospective
and controlled clinical chronic studies exploring any overlap
between blood-based biomarker profiles in AD pathogenesis
and following repetitive mTBI. We hypothesized that a
comprehensive characterization of molecular changes in the
plasma of mouse models of these conditions will help to identify
putative biomarkers that might have translational potential in
identifying repetitive mTBI patients that are at risk for AD. We
have utilized a proteomic approach to analyze blood samples
from our in-house repetitive mTBI model in wild-type mice
(Mouzon et al., 2012; Ojo et al., 2013; Mouzon et al., 2014,
2018a,b; Ojo et al., 2015), and the PSAPP [(PS1(M146L),
APP(K670N, M671L)] and hTau [expressing all six isoforms of
human tau, and lacking expression of murine tau] mouse models
of AD that develop primarily amyloid and tau-based pathologies,
respectively (Holcomb et al., 1998; Andorfer et al., 2003).
Our mass-spectrometry based approaches have generated a
unique and detailed time-course of the molecular response
to repetitive mTBI from 24 h to 12 months post-injury, and
in AD models encompassing pre-, peri-, and post-“onset” of
pathological phenotypes (3–15 months of age). Our data reveal
unique and common mTBI-dependent and AD-progression
dependent molecular level changes in the TBI and AD mouse
model compared to their relevant controls.
Unique Proteomic Changes in Blood
Based Markers Following Repetitive
mTBI
In the repetitive mTBI study, we identified 13 different
proteins that were unique to the injury group alone and
were changing over multiple time points post-injury. These
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TABLE 4 | List of common and unique significantly modulated proteins in plasma
samples from repetitive mTBI, hTau, and PSAPP mice across all time points and
ages.
M.P.A Description r-mTBI hTau PSAPP
P07758 Alpha-l-antitrypsin 1–1 0 1 0
Q00896 Alpha-1-antitrypsin 1–3 0 0 1
Q00897 Alpha-l-antitrypsin 1–4 1 0 0
Q00898 Alpha-l-antitrypsin 1–5 1 1 1
Q61247 Alpha-2-antiplasmin 1 0 0
P29699 Alpha-2-HS-glycoprotein 1 1 0
Q61838 Alpha-2-macroglobulin 1 0 1
Q9QZ39 ST6GALNAC1 1 0 0
P32261 Antithrombin-III 1 0 0
Q00623 Apolipoprotein A-I 1 1 1
P09813 Apolipoprotein A-II 1 0 0
P06728 Apolipoprotein A-IV 1 0 1
P34928 Apolipoprotein C-l 1 0 0
Q9Z1R3 Apolipoprotein M 0 0 1
Q01339 Beta-2-glycoprotein 1 1 0 0
A8DUK4 Beta-globin 1 1 0
P08607 C4b-binding protein 1 0 0
P23953 Carboxylesterase 1C 1 0 0
Q9DBB9 Carboxypeptidase N
subunit 2
1 0 0
Q06890 Clusterin 1 1 0
Q80YC5 Coagulation factor XII 0 1 0
P06909 Complement factor H 1 0 0
Q61129 Complement factor I 1 0 0
Q06770 Corticosteroid-binding
globulin
1 1 0
Q9QXC1 Fetuin-B 1 0 0
P11276 Fibronectin 1 0 0
P01898 H2Q10 alpha chain 1 1 0
Q61646 Haptoglobin 1 0 0
P01942 Hemoglobin subunit alpha 1 1 0
Q91X72 Hemopexin 1 1 1
P01869 Ig gamma-1 chain C region 1 0 0
(Continued)
TABLE 4 | Continued
M.P.A Description r-mTBI hTau PSAPP
P01867 Ig gamma-2B chain C
region
1 0 0
P06330 Ig heavy chain V region
AC38 205.12
1 0 0
P01837 Ig kappa chain C region 1 1 1
P01644 Ig kappa chain V–V region
HP R16.7
1 0 0
P01872 Ig mu chain C region 1 1 1
Q61730 lnterleukin-1 receptor
accessory protein
1 0 0
008677 Kininogen-1 1 1 0
Q91XL1 Leucine-rich HEV
glycoprotein
1 0 0
P28665 Murinoglobulin-1 1 1 0
D3YXF5 Oxidation resistance
protein 1
1 0 0
P20918 Plasminogen 1 0 1
F6TQW2 Protein Ighg2c 1 1 0
A0A0B4J1N0 Protein lghvl-76 1 0 0
A0A0A6YWH6 Protein lghv9-4 (Fragment) 1 0 0
A0A075B5M7 Protein lgkv5-39 0 0 1
P19221 Prothrombin 1 0 0
Q00724 Retinol-binding protein 4 1 1 0
P07759 Serine protease inhibitor
A3K
1 1 0
Q91WP6 Serine protease inhibitor
A3N
1 0 0
Q921I1 Serotransferrin 1 0 1
P07724 Serum albumin 1 1 1
P61939 Thyroxine-binding globulin 0 1 0
P07309 Transthyretin 1 1 0
P21614 Vitamin D-binding protein 1 0 0
Venn diagram and table shows number of common and unique significantly
regulated proteins in all three different mouse models (0 – not significant; 1 –
significant). MPA, Master protein accessions.
proteins were mainly serine protease enzymes (such as:
alpha-1-antitrypsin 1–4, alpha-2-antiplasmin, plasminogen, anti-
thrombin-III, prothrombin) and metalloproteinase enzymes
(such as carboxypeptidase N) which have a role in an array of
biological processes, including coagulation, inflammation and
biosynthesis of neuroendocrine peptides. We also identified
immunoglobulins (protein ighv9-4) involved in B cell signaling,
antigen binding and phagocytosis; carrier proteins involved in
the transport of hormones (transthyretin and corticosterone
binding globulin); molecular chaperones (such as clusterin) and
inflammatory proteins (complement factor I and IL-1 receptor
accessory protein). The top three canonical pathways modulated
involved LXR/RXR pathway, complement system and production
of nitric oxide and reactive oxygen species. The LXR/RXR
pathway is involved in a host of pleiotropic effects ranging from
inflammation, lipid biogenesis, energy metabolism and oxidative
stress. The complement system is primarily involved in the innate
immune response by sentinel cells. The production of nitric oxide
and reactive oxygen species are byproducts of metabolism of
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oxygen, and their accumulation can result in oxidative stress and
cellular oxidative damage. The direction of change in the levels
of identified proteins in the majority of cases involved an initial
trend in injured versus sham mice toward decrease at the 3-
months post-injury time point compared to levels at 24 h (owing
to the initial increased spike at 24 h post-injury), and thereafter a
gradual increase was observed at later chronic time points (6, 9,
and 12 months).
We employed an ELISA approach to validate our findings
for three different proteins, which confirmed a similar trend
in the groups assessed. Our previous neurobehavioral work
in this injury model demonstrate deficits in spatial learning
and memory processing as early as 1-week post-injury, which
persists until 6 months and remains significant compared
to shams at 12, 18, and 24-months post-injury time points
(Mouzon et al., 2012, 2014, 2018b). Neuropathological studies
also demonstrate significant axonal injury and gliosis 24 h and
3-months post-injury (Mouzon et al., 2012; Ojo et al., 2015),
with the neuropathological lesions still present albeit to a lesser
degree at the 6-month time point and thereafter persisting and
progressively worsening between the 12–24 months post-injury
time points (Mouzon et al., 2014, 2018b). These sequelae of events
unique to the repetitive mTBI mice seem to echo the same pattern
of changes observed in the plasma, whereby we observed an
initial response consistent with ongoing brain reparative process
attempting to resolve the consequences of the acute secondary
injury, but failing to return to normal sham levels or phenotype,
and gradually worsening into later chronic time points post-
injury.
In addition to these unique r-mTBI dependent changes, we
also observed that unique and distinct age-related changes in
sham mice (i.e., normal and non-pathological aging profiles)
were not observed in the r-mTBI group with aging, these normal
age-related changes were typified by alterations in proteins
involved in lipid, vitamin, and oxygen transport (apolipoprotein
A-II, retinol-binding protein 4, beta globin), and regulation of
serine protease activity (Fetuin-B, serine protease inhibitor A3N),
implicating age-related impairment in the physiological role of
these proteins in injured animals. Additionally, there were also 28
age-related proteins in our r-mTBI model that showed a common
age-related pattern of change in sham mice, albeit to a different
degree in most cases.
Given the very focal nature of our experimental injury to the
brain, the etiology of early changes in plasma biomarkers may
be directly or indirectly mediated by localized neuronal, glial or
vascular injury in the brain. TBI can initially result in a transient
opening of the blood brain barrier, or increased eﬄux of ISF/CSF
drainage pathways into the blood or lymphatic vessels that can
activate a series of events in the periphery resulting in changes
in blood-based protein profiles. The etiology and specificity of
the identified plasma changes in our mTBI model are currently
unknown, and further studies will be needed to validate their
utility as biomarkers and to investigate what they may contribute
to our understanding of mTBI pathogenesis. Ideally the most
attractive plasma biomarkers are those which can adequately
track the neurological changes in the brain (irrespective of
involvement in pathogenesis), and more specifically be utilized as
a prognostic tool for management of mTBI patients beyond the
initial exposure to injuries.
Most blood-based clinical biomarker research to date has
focused on evaluating moderate to severe TBI (Kochanek et al.,
2008; Svetlov et al., 2009; Dash et al., 2010; Yokobori et al., 2013),
with only a few studies investigating mTBI. Because the cascade
of secondary injury involves astrocytic/microglial activation,
axonal degeneration, excitotoxicity, mitochondrial dysfunction,
and lipid peroxidation, biomarker studies have focused primarily
on identifying proteins related to these processes. For example
those abundant in astroglia [S100B, Glial Fibrillary Acidic Protein
(GFAP)], neurons [Neuron Specific Enolase (NSE), Ubiquitin
C-Terminal Hydrolase-L1- (UCHL1)], oligodendrocytes (Myelin
Basic Protein); neuronal cytoskeletal proteins (Spectrin Break
Down Products, Tau, Neurofilament), inflammatory cytokines,
metabolites, and oxidized lipids (Pineda et al., 2004; Kochanek
et al., 2008; Svetlov et al., 2009; Dash et al., 2010; Sandler et al.,
2010; Giacoppo et al., 2012; Yokobori et al., 2013; Papa et al.,
2015a,b, 2016; Siman et al., 2015; Welch et al., 2016, 2017; Gill
et al., 2018; Oliver et al., 2018; Shahim et al., 2018). Specifically,
S100B, UCHL1, NSE, GFAP and tau have been the most studied
candidates. Investigators have shown good correlation with mTBI
and neurological outcome at acute time points with some of these
markers (de Kruijk et al., 2001; Papa et al., 2011a,b, 2016; Berger
et al., 2012; Giacoppo et al., 2012; Neselius et al., 2013b; Shahim
et al., 2014, 2018; Olivera et al., 2015; Rubenstein et al., 2015;
Mondello et al., 2016; Welch et al., 2016, 2017; Oliver et al., 2018).
Likewise, preclinical biomarker studies in plasma samples that
have focused on markers associated with the cascade of secondary
injury from closed head TBI, weight drop, and blast models in
rodents and pigs with a variety of frequency and injury severities
have also revealed elevations in inflammatory/protease markers,
astroglial, axonal, and vascular proteins (Gyorgy et al., 2011;
Rostami et al., 2012; Ahmed et al., 2012; Chase, 2014; Sharma
et al., 2017). Similar to the human studies, the preclinical work
has largely been limited to changes at acute to subacute time
points (most <3 months post-injury).
Despite the number of studies conducted to identify clinical
biomarkers for TBI, very few candidates have progressed into
clinical trials. The most notable markers identified by the Banyan
group (GFAP and UCHL1) have shown some relative success
in a few clinical studies, and has recently been authorized for
marketing by the FDA as the first blood test to aid in the
acute evaluation of concussion in adults (Okonkwo et al., 2013;
Papa et al., 2016; Welch et al., 2017). Nonetheless, despite the
success of these markers, other groups have reported negative
results in clinical studies of mild CT-negative traumatic brain
injury patients (Tenovuo et al., 2016), and in a multi-center
TRACK-TBI observational study involving mTBI patients (Diaz-
Arrastia et al., 2014; see also Mondello et al., 2017). This lack of
coherent data could be attributed to the fact that some glial and
neuronal proteins can be derived extracranially from other cells,
while some can be released into serum during hemolysis, and
others can be detected in comorbid conditions such as ischemic
reperfusion injury, myocardial ischemia and non-cranial trauma
(Anderson et al., 2001; Pelinka et al., 2004; Ohrt-Nissen et al.,
2011). Additionally, a specific and sensitive chronic-related
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FIGURE 6 | Canonical pathways modulated in PSAPP vs. wild type littermate control mice across multiple time points post-injury. Identified canonical pathways
generated from the list of significantly modulated proteins in wild type and PSAPP groups across different ages using IPA. Top three pathways include Production of
Nitric oxide and Reactive oxygen species, Acute phase response signaling, LXR/RXR activation.
FIGURE 7 | Canonical pathways modulated in hTau vs. wild type C57BL/6J mice across multiple time points post-injury. Identified canonical pathways generated
from the list of significantly modulated proteins in wild type and hTau groups across different ages using IPA. Top three pathways include coagulation system,
LXR/RXR activation, Production of Nitric oxide and Reactive oxygen species.
biomarker for asymptomatic individuals at risk for developing
neurodegenerative diseases many years after exposure to a history
of multiple mTBI’s also still remains lacking.
A major limitation of using CNS derived brain cell
specific proteins as a TBI marker in plasma is the fact
that most intracellular proteins released into the bloodstream
undergo degradation and/or modification by proteases and other
enzymes, and their normal half-life is unknown in most cases.
Moreover, the dilution of CNS proteins into 4 L of blood
containing an extraordinarily high protein concentration (60–
80 g/L protein) compared to 150 ml of CSF with a protein
concentration of 0.15–0.45 g/L contributes significantly to the
low concentrations of CNS-derived molecules in the blood, and
the difficulty in identifying consistent qualitative and quantitative
changes in this complex blood proteome. This was indeed a
limitation of this current study, because the majority of master
protein groups identified in our plasma samples are in relatively
high abundance in this biofluid, thus ultrasensitive changes to
low abundant brain derived proteins in the plasma milieu may
not have been adequately captured using our LC/MS approach.
Nonetheless these findings do indicate that repetitive mTBI can
initiate a series of persistent and unique changes in the periphery.
More work will be needed to demonstrate the specificity to
r-mTBI from our preclinical studies, the validity (and specificity)
for human r-mTBI, whether the biomarkers are directly from
brain insult or from downstream consequences of brain insult,
and finally whether these insights might shed some light on the
brain pathobiological sequelae.
In human studies very few unbiased proteomic approaches
have been conducted in mTBI. Gao et al. (2014) evaluated serum
(within 12 h post-injury) from infants that had sustained a
mild abusive head injury (AHI). Using a 2D-DIGE combined
with LC-MS, they identified serum amyloid A protein, an acute
phase reactant and non-specific marker of inflammation that
showed high specificity for AHI. This injury was, however,
associated with acute extra-axial hemorrhage which is not
common in most mTBI cases of this nature. Human studies have
to be interpreted with caution, particularly because of inherent
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limitations such as the heterogeneity in population, trauma type
and severity, lack of large scale prospective studies, underlying
comorbidities and confounding conditions [for example, it is
noteworthy to consider Plog et al. (2015) showing the impact
of sleep and cisternostomy on glymphatic clearance and TBI
markers]. More chronic longitudinal studies are thus needed,
particularly involving very broad based unbiased approaches in
a highly controlled setting to identify specific proteins that can
then be investigated in a targeted fashion in the much more
complex human population as we have done herein, and which
underscores the value and design of our current study herein.
Longitudinal animal studies exploring unbiased biomarkers
of TBI in the plasma are very sparse. We could only find our
previous study on mild to severe CCI in APOE3 and APOE4
mice as an example (Crawford et al., 2012). Plasma (collected
at 24 h and 1 month after injury) was analyzed using LC-MS,
and 30 proteins were identified as being significantly modulated
in the TBI mice over the two different time points post-
injury. Bioinformatics analysis of proteins modulated after injury
identified functions known to be associated with TBI such as
the acute phase response, oxidative stress, and lipid metabolism,
which parallel some of the changes we observed here.
Coincidental Changes in mTBI and AD
Blood Based Biomarkers
In this study we explored the areas of molecular overlap
that may represent critical elements of the TBI and AD
pathogenic interrelationships in the plasma. Using Ingenuity
Pathway Analysis (IPA) which provides functional interpretation
of observed changes, we identified key related molecules and
pathways common to age-related changes in AD models
and chronic post-injury changes in our mTBI model. This
involved Production of nitric oxide and reactive oxygen species,
LXR/RXR activation and upregulation of inflammatory responses.
Ten and eighteen proteins were found to consistently change
between mTBI vs. PSAPP models and mTBI vs. hTau models,
respectively. Some of these proteins include alpha-1-antitrypsin,
apolipoprotein A-1, hemopexin, Ig k chain C, Ig µ chain
C, serum albumin, serotransferrin, plasminogen, alpha-2-
macroglobulin, corticosteroid-binding globulin, clusterin and
transthyretin. These significantly regulated proteins are primarily
involved in (i) sequestration and precipitation of proteinaceous
aggregates; (ii) mediating clearance by receptor mediated
endocytic mechanisms; (iii) antigen presentation; (iv) mediating
inflammation/oxidative stress mechanism; and (v) transporter
proteins. The changes observed in both hTau and PSAPP
models were present in older mice (aged 9–15 months)
when neuropathological lesions correlate strongly with cognitive
deficits. For example, PSAPP mice reportedly show normal
acquisition in learning and working memory in the radial arm
water maze between 6 and 9 months when neuropathology is
minimal, but exhibit progressive, age-related deterioration in the
performance of these cognitive tasks by 15–17 months (Holcomb
et al., 1998; Arendash et al., 2001; Gordon et al., 2002). hTau mice
begin to demonstrate impairment in normal object-recognition
memory and spatial learning/memory assessed by the Morris
Water Maze by >12 months of age (Polydoro et al., 2009). To
our knowledge our work is the first comprehensive unbiased
proteomic approach used to identify common blood biomarkers
in a controlled longitudinal preclinical study in TBI and AD
models.
In support of our findings, human studies over the last decades
have implicated several plasma proteins in AD pathobiology
(Baird et al., 2015), some of which we have identified in both
our TBI and AD mouse study. Increased Apolipoprotein IV
levels, a lipoprotein that facilitates uptake of amyloid protein has
been identified in serum samples of AD (Yang et al., 2012), and
codon 360 mutation in patients has also been associated with AD
(Csaszar et al., 1997). Gupta et al. (2013) showed that the levels of
another apolipoprotein plasma protein [ApoE] in AD revealed
an obvious relationship between its levels and AD diagnosis.
Lipoprotein, clusterin has been correlated with brain atrophy,
and MCI, and is found in blood and brain tissue surrounding
amyloid plaques (Thambisetty et al., 2010a, 2012; Jongbloed et al.,
2015). Variants in clusterin are associated with the risks of AD
(Harold et al., 2009; Lambert et al., 2009). Transthyretin, a carrier
protein for thyroxine and retinol in plasma and cerebrospinal
fluid (CSF) that sequesters proteinaceous aggregates is reduced
in AD (Sousa et al., 2007; Thambisetty et al., 2010b; Velayudhan
et al., 2012). Protease scavenger, alpha-2-macroglobulin has also
been identified in plasma and CSF biomarker studies, and can
be found in senile plaques, it has also been genetically associated
with AD (Blacker et al., 1998; Kovacs, 2000; Lovestone et al.,
2009; Zabel et al., 2012; Hye et al., 2006, 2014). Iron binding
protein, serotransferrin which mitigates the impact of iron on
precipitating amyloid aggregation has been reported in the CSF
and blood of MCI and AD patients (Wildsmith et al., 2014). Other
proteins reported include increased serum α-1-antichymotrypsin
that participates in the inflammatory cascade of AD and enhances
the formation of amyloid fibrils (Kamboh et al., 1995, 2006; Guan
et al., 2012; Tyagi et al., 2013); upregulation in interleukins (IL-
1α, IL-6) (Du et al., 2000; Grimaldi et al., 2000; Leung et al.,
2013) and downregulation of activity-dependent neuroprotective
proteins (Yang et al., 2012). The findings from the majority of
these human biomarker studies seems to corroborate with our
work herein, as we have demonstrated similar protein changes to
these human AD plasma proteomic studies. Further studies will
be needed to capitalize on our vast preclinical molecular library
of omic data, to explore prospective and translatable approaches
for validation and utility of putative biomarkers that may provide
an insight into the link between TBI and increased AD risk.
Limitations
A limitation of this study and other plasma proteomic studies is
the efficient and comprehensive depletion of abundant plasma
proteins, as it is well-known that their presence in a sample
can hamper efforts to identify and quantify novel circulating
biomarkers which are typically much lower in abundance. We
used an approach described in the Material and Methods
section – namely, the use of a 58% HFIPA solution to selectively
re-suspend an essentially albumin- and hemoglobin-depleted
protein fraction from a methanolic precipitate, which enables
the generation of what is typically the “throwaway pellet” that
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could be used as part of a larger poly-mic (i.e., lipidomic and
metabolomics) workflow from a single aliquot of material, which
we planned for this current study. We have previously described
this approach at the American Society for Mass spectrometry
conference (Reed et al., 2013, 2014), and a separate manuscript
describing this approach is under construction (Reed et al., pers
comm). While we acknowledge that the protein fractionation
component of our overall workflow may not perform as well
as conventional immunoaffinity depletion protocols (example.,
Top12 or Mouse 3 spin columns from Pierce or Agilent,
respectively), we have observed that it performs on par with
other solvent-based depletion protocols (Reed et al., 2013, 2014),
such as the modified Cohn precipitation first described by
the van Eyk group (Fu et al., 2005, 2007), and subsequently
modified and adapted for use in our plasma proteomics work
(Crawford et al., 2012).
Technical reproducibility was key to this protocol during
development and in-house validation, and we observed highly
consistent sample preparations from technician to technician
using pooled plasma samples. As technical variation was
exceedingly minimal, we are confident in the assessment that
sample-to-sample variations which are observed are primarily
rooted in the sample itself. Transferrin and IgG proteins do,
however, co-purify using this fractionation, as we have yet to
devise additional steps to reproducibly ensure their removal. We
thus acknowledge that this obviously contributes to DDA-LCMS
sampling bias, and is an acknowledged limitation of the assay.
In our data presentation we have listed several known abundant
plasma proteins as being differentially expressed following
statistical filtering. This was done to attempt to minimize bias
as much as possible, and include proteins – abundant or not –
into such tables as they are what the statistical analyses and
the TMT data has indicated were unique to treatment groups.
Thus removing them based on pre-suppositions regarding their
relevance as a function of abundance, would have added an
additional layer of bias, as well as compromise the intentions of
our statistical analysis. To that end, we performed validations
on a subset of these markers using an orthogonal bioanalytical
approach (ELISA), and observed that the trends observed in
the TMT analysis were recapitulated using an immunological
assay.
Additionally, we also acknowledge that the models we have
used may not directly represent the best platforms to explore the
increased risk of repetitive mTBI contributing to the development
of AD related amyloid and tau pathogenesis. This is particularly
because we have used wild-type mice in our studies which do
not develop tau pathogenesis nor amyloid plaques. We have
examined this repetitive mTBI paradigm in our previous work
at 24 h, 6, 12, 18, and 24 months post-injury, and report no tau
or amyloid pathology from our comprehensive histopathological
and biochemical analyses (Mouzon et al., 2012, 2014, 2018b).
We recognize that more relevant humanized hTau or APP knock
in mice will be required to properly address this question, as
such we acknowledge that we cannot definitively describe the
overlapping changes in our model as attributed to increased
repetitive mTBI risk for AD pathogenesis. Previous studies
have demonstrated the behavioral profiles in hTau and PSAPP
mice as we have previously described (see above), and it is
worth mentioning that we have also previously documented
behavioral (i.e., persistent spatial learning impairment) and
histopathological findings (typified by persistent axonal injury
and gliosis) in our wild type mouse model from 24 h to 24 months
post-injury, indicating that behavioral deficits in this model
are mediated by a non-tau/amyloid mechanism. Indeed, in this
same cohort we have conducted proteomics analyses of brain
tissue at the same time points of analyses described in this
current work, and we present distinct and overlapping proteomic
response to injury in our TBI model compared with AD mouse
models, indicating a distinct TBI mediated neurodegeneration
(not related to tau or amyloid pathology), that also shares features
with AD pathogenesis (Ojo et al., pers comm). One of the main
common features observed in both TBI and AD models from our
proteomic work is glial pathobiology which we are exploring in
current work.
CONCLUSION
We hypothesized that controlled preclinical studies in mouse
models that demonstrate TBI sequelae and AD pathogenesis
would identify areas of molecular overlap that may represent
critical elements in the pathogenic interrelationship between
TBI and AD. Our unbiased mass-spectrometry based proteomic
approach has generated extensive qualitative and quantitative
data sets that provide a unique and detailed time-course of
the molecular response to repetitive mTBI and AD pathology,
in mouse models, at a level not previously examined. Our
comprehensive in depth interrogation has identified novel
longitudinal plasma biomarker profiles in our injury model.
We also reveal TBI-dependent molecular overlap in our injury
model which are consistent with age-dependent changes in our
AD models. The unique and convergent molecules in the TBI
and AD plasma profiles represent candidates for investigation
in human prospective studies as potential biomarkers that
could aid risk assessment for TBI patients (such as informed
decision-making regarding return to duty and deployment
choices for active duty soldiers, and return to play for athletes
involved in contacts sports) and possible AD prognosis, including
evaluation of treatment (as theragnostic or pharmacodynamics
endpoint markers) before a patient’s condition is exacerbated.
Given the lack of tau and amyloid pathogenesis in our wild
type TBI model, the impact of repetitive mTBI on AD risk
biomarkers should be interpreted with caution due to the lack
of existent AD pathology in our model. Our brain proteomic
studies (Ojo et al., pers comm) have indicated a distinct TBI
mediated neurodegeneration, which shares some overlap with
AD pathogenesis in the hTau and PSAPP models, that is not
primarily mediated by tau or amyloid pathogenesis in our model.
We thus acknowledge that further studies will be required in
humanized hTau and APP knock in mice to further explore
the role of these overlapping biomarkers as a TBI induced
AD risk. Additional studies will also be needed to assess the
specificity and selectivity of these biomarkers in diagnosing
mTBI and predicting outcome in longitudinal cohorts of mTBI
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patients. The biomarkers themselves, and their up- and down-
stream mediators, may shed light on mTBI pathogenesis, which
will first be explored in additional preclinical studies.
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FIGURE S1 | Validation of changes in plasma complement factor I expression
levels using antibody based ELISA approach in repetitive mTBI mice at multiple
time points post-injury. (A) Represents ratio of BCA corrected ELISA
concentration values normalized to 24 h post-injury time point for repetitive mTBI
only group. (B) Represents values from proteomic analyses using TMT
labeling normalized to 24 h post-injury time point for repetitive mTBI only
group.
FIGURE S2 | Validation of changes in plasma LRG expression levels using
antibody based ELISA approach in repetitive mTBI mice at multiple time points
post-injury. (A) Represents ratio of BCA corrected ELISA concentration values
normalized to 24 h post-injury time point for repetitive mTBI only group. (B)
Represents values from proteomic analyses using TMT labeling normalized to 24 h
post-injury time point for repetitive mTBI only group.
FIGURE S3 | Validation of changes in plasma alpha-2-macroglobulin expression
levels using antibody based ELISA approach in sham and repetitive mTBI mice at
multiple time points post-injury. (A) Represents ratio of BCA corrected ELISA
concentration values normalized to 24 h post-injury time point for sham and
repetitive mTBI only group. (B) Represents values from proteomic analyses using
TMT labeling normalized to 24 h post-injury time point for sham and repetitive
mTBI only group.
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